Arsenic Trioxide 10mg Injection

Arsenic Trioxide 10mg Injection is a remarkable pharmacological agent that transformed a historically feared poison into a life-saving cure for Acute Promyelocytic Leukemia (APL). Acting as a targeted antineoplastic agent, it works by specifically attacking the PML-RARA fusion protein, the genetic driver of this specific leukemia. At the molecular level, Arsenic Trioxide induces the ubiquitination and subsequent degradation of this fusion protein by the proteasome. This destruction has a dual effect: at lower doses, it promotes the differentiation of immature leukemic cells into functioning white blood cells; at higher concentrations, it triggers apoptosis (programmed cell death) by damaging the mitochondria of the cancer cells. When combined with All-Trans Retinoic Acid (ATRA), it forms a synergistic “chemotherapy-free” regimen that attacks the cancer from two distinct angles, offering the highest cure rates in the history of this disease. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for molecular remission, turning a once-fatal diagnosis into a highly manageable condition.

The 10mg/10mL (1 mg/mL) ampoule is the standard liquid formulation designed for intravenous infusion. The dosing is strictly weight-based, typically administered at 0.15 mg/kg daily until bone marrow remission is achieved. The 10mg unit facilitates precise volume calculations for compounding into saline or dextrose infusions. This formulation is critical for both the induction phase (to achieve remission) and the consolidation phase (to eliminate any remaining microscopic disease), ensuring a sustained therapeutic attack on the leukemic clone.

Indications / Uses of Arsenic Trioxide 10mg Injection

Arsenic Trioxide 10mg Injection is commonly prescribed for the specialized management of the following hematological malignancy:

• Acute Promyelocytic Leukemia (APL): It is indicated for the induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RARA gene expression.
• First-Line APL Treatment: In modern protocols, it is increasingly used as a first-line treatment in combination with Tretinoin (ATRA) for low-to-intermediate risk APL, allowing many patients to avoid traditional cytotoxic chemotherapy entirely.

Key Features

• PML-RARA Degrader: The primary feature of Arsenic Trioxide is its ability to physically degrade the cancer-causing fusion protein, restoring normal cell regulation.
• Dual Mechanism: It uniquely induces both cell differentiation (maturation) and apoptosis (death) in leukemic cells depending on the concentration.
• High Cure Potential: When combined with ATRA, it achieves durable cure rates exceeding 90% in standard-risk patients.
• Non-Cross Resistant: It remains effective even in patients who have developed resistance to standard chemotherapy drugs.
• 10mg Standard Strength: The 1 mg/mL concentration simplifies the preparation of weight-based daily infusions.

Storage for Arsenic Trioxide 10mg Injection

To preserve the chemical stability and ultimate potency of the active ingredients, Arsenic Trioxide 10mg Injection should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Do not freeze the ampoules. It is vital to keep the medication in its original packaging until ready for use. Diluted solutions (in IV bags) are stable for 24 hours at room temperature and 48 hours when refrigerated. Store the medication in a secure, professional medical environment strictly out of the reach of children.

Important Note on Arsenic Trioxide 10mg Injection

The administration of Arsenic Trioxide 10mg Injection is associated with two major Black Box Warnings. First, APL Differentiation Syndrome can occur, characterized by fever, dyspnea, weight gain, and pulmonary infiltrates. This is a medical emergency treated with high-dose dexamethasone immediately upon suspicion.

Second, QT Interval Prolongation is a significant cardiac risk that can lead to Torsade de Pointes (a fatal arrhythmia). Strict Electrolyte Monitoring is mandatory: Potassium (K+) must be maintained above 4.0 mEq/L and Magnesium (Mg++) above 1.8 mg/dL throughout treatment. Electrocardiograms (ECGs) should be performed weekly or more frequently in unstable patients.

Arsenic Toxicity: Although used therapeutically, signs of acute arsenic toxicity (convulsions, muscle weakness, confusion) should be monitored. Arsenic Trioxide 10mg Injection can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and cardiac monitoring protocols, healthcare providers can safely maximize the curative power of Arsenic Trioxide 10mg Injection.